Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach

CONCLUSIONS: PAD interventionalists practicing at an academic health system recognize the heterogenous response of their patients to clopidogrel therapy but are unsure when to leverage genetic testing to improve outcomes for their patients. Our study identified gaps regarding PAD interventionalists' knowledge, perceived barriers, and attitudes toward CYP2C19 testing in PAD. This information highlights the need for randomized data on genetic testing for clopidogrel responsiveness in peripheral vascular disease following intervention to help guide antiplatelet management.PMID:38669051 | DOI:10.1177/17085381241246318

Source: Vascular - April 26, 2024 Category: Surgery Authors: Christopher Regan Lindsey E Scierka Alan Dardik Britt Tonnessen Cassius Iyad Ochoa Chaar Costin Ionescu Edouard Aboian Jonathan Cardella Naiem Nassiri Raul Guzman Robert Attaran Sameer Nagpal Samit Shah Kim G Smolderen Carlos Mena-Hurtado Source Type: research